Ion Channel Remodeling in HCM
Definition
Ion channel remodeling in hypertrophic cardiomyopathy (HCM) refers to disease-specific changes in the expression and function of cardiac ion channels — increases in inward currents (INaL, ILTCC) and decreases in repolarizing K⁺ currents — that collectively prolong action potential duration (APD), predispose to triggered activities (EADs and DADs), and create substrate for ventricular arrhythmia and sudden cardiac death. Critically, these changes can precede structural remodeling (hypertrophy and fibrosis), making them relevant targets for early-stage HCM.
Key Concepts
Pattern of Ion Channel Changes
- ↑INaL (late sodium current): Enhanced late Na⁺ entry prolongs APD plateau; impairs NCX function → intracellular Na⁺ and then Ca²⁺ accumulation during diastole. (sources/HCM-VA-FCVMed-2022)
- ↑ILTCC (L-type Ca²⁺ channel current): Enhanced Ca²⁺ entry during systole; phosphorylation of LTCC β-subunits by CaMKII slows inactivation. (sources/HCM-VA-FCVMed-2022)
- ↓K⁺ currents: Reduced Kir2.1/IK1 (inward rectifier), Kv4.3/Ito (transient outward), IKs and IKr (delayed rectifier) → impaired repolarization reserve. (sources/HCM-VA-FCVMed-2022)
- Net effect: APD prolongation → APD alternans and early afterdepolarizations (EADs) → triggered ventricular arrhythmia. (sources/HCM-VA-FCVMed-2022)
CaMKII as the Central Bridge
- Calcium-calmodulin-dependent protein kinase II (CaMKII) bridges sarcomere gene mutations → ion channel remodeling. (sources/HCM-VA-FCVMed-2022)
- Sequence of events:
- Sarcomere mutation → initial cytosolic Ca²⁺ accumulation
- CaMKII autophosphorylation → increased activity
- Phosphorylation of LTCC β-subunits → slowed inactivation → ↑ILTCC
- Phosphorylation of Nav1.5 → altered INa inactivation → ↑INaL
- ↑INaL → NCX impairment → further diastolic Ca²⁺ accumulation → further CaMKII activation (positive feedback loop)
- This "posttranslational modification" mechanism is common across multiple HCM experimental models. (sources/HCM-VA-FCVMed-2022)
Early-Stage Onset
- In TNNT2-R92Q mice, INaL increase is detectable at 4 weeks of age — before hypertrophy and diastolic dysfunction (which develop at ~6 months). (sources/HCM-VA-FCVMed-2022)
- Lifelong ranolazine treatment prevented most downstream abnormalities in this model: normalized INaL density, K⁺ channel gene expression, Ca²⁺ transient, and spontaneous diastolic depolarization. (sources/HCM-VA-FCVMed-2022)
- Clinically, this supports consideration of prophylactic INaL inhibition in young HCM patients with high-risk gene mutations before phenotypic manifestation. (sources/HCM-VA-FCVMed-2022)
hiPSC-CM Confirmation
- MYH7-R442G hiPSC-CMs from HCM patients: prolonged APD50/APD90, ↑Ca²⁺ current, ↑INaL, K⁺ current abnormality — mirroring adult HCM myocyte changes. (sources/HCM-VA-FCVMed-2022)
- ACTN2-T247M EHT (3D): prolonged APD50/90, ↑Ca²⁺ current, ↑AP amplitude. (sources/HCM-VA-FCVMed-2022)
Heterogeneous Remodeling and Dispersion of Repolarization
- Ion channel remodeling is unevenly distributed across the LV; areas of severe dysfunction coexist with normal areas. (sources/HCM-VA-FCVMed-2022)
- Increased dispersion of repolarization → persistent reentry circuit formation → sustained ventricular arrhythmia. (sources/HCM-VA-FCVMed-2022)
Transverse Tubule Disruption
- TT destruction/redistribution impairs synchronous SR Ca²⁺ release → APD increase + ERP alternation → reentry circuits. (sources/HCM-VA-FCVMed-2022)
- Confirmed in the Δ160E cTnT HCM mouse model. (sources/HCM-VA-FCVMed-2022)
Contradictions / Open Questions
- Mouse model findings not replicated in human tissue: K⁺ current reductions observed in Mybpc3-KI mice were not replicated in human MYBPC3-homozygous engineered heart tissue (EHT) or human LV septum specimens from HCM patients undergoing myectomy. This is a documented species translational gap — the specific ion channel remodeling pattern in mice may not represent the human disease mechanism. (sources/HCM-VA-FCVMed-2022)
- Pre-structural ION changes — clinical action threshold undefined: INaL elevation precedes structural remodeling in TNNT2-R92Q mice (detectable at 4 weeks, before hypertrophy at 6 months). The clinical correlate — whether ion channel changes exist in gene-positive but phenotype-negative human patients — has not been validated. The proposed prophylactic INaL inhibition (ranolazine) in asymptomatic gene-positive patients is biologically motivated but remains a clinical hypothesis without human trial evidence. (sources/HCM-VA-FCVMed-2022)
Connections
- Related to entities/HCM
- Related to concepts/Calcium-Homeostasis-in-HCM
- Related to concepts/Cardiac-Action-Potential
- Related to concepts/Ion-Channel-Mutations
- Related to entities/MYBPC3
- Related to entities/MYH7
- Related to concepts/HCM-Risk-SCD
- Related to concepts/Sudden-Cardiac-Death